Harsco Pharmaceutical’s innovative drug HSK50042 tablets receive clinical approval for a new indication
March 6, 2026
Source: drugdu
27
on the evening of March 5th that Harsco Pharmaceutical...(002653) issued an announcement stating that its subsidiary, Shanghai Haishengnuo Pharmaceutical Technology Co., Ltd., recently received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration, with the indication being respiratory diseases.
Harsco Pharmaceuticals stated that HSK50042 tablets are an orally administered, potent, and highly selective small molecule inhibitor independently developed by the company. This latest approval for a new indication in the field of respiratory diseases marks another significant milestone in its clinical trials. Preclinical studies have shown that HSK50042 can effectively improve the pathological symptoms of lung diseases in model mice at relatively low doses, demonstrating good efficacy, good tolerability, and a large safety window. It is a drug with great development potential and is expected to provide patients with respiratory diseases with a highly effective and safe new treatment option.
https://finance.eastmoney.com/a/202603053663302749.html
By editor
Copyright©2026 Ddu. All rights reserved.
Read more on
- Anglikang Adenosylcobalamin Capsules Obtain Drug Registration Certificate March 6, 2026
- Two Minoxidil Topical Solution Applications from its Subsidiary Approved March 6, 2026
- Zhejiang Medicine’s ARX305 Initiates Phase II Clinical Trial March 6, 2026
- Indacaterol Mometasone Inhalation Powder Clinical Trial Approved for Asthma Treatment March 6, 2026
- Clinical trial application for HLX97 approved by the National Medical Products Administration March 6, 2026
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
